Regeneron and Sanofi’s Praluent gets European approval for reducing cardiovascular risk in atherosclerotic disease patients
Regeneron Pharmaceuticals and Sanofi have received a significant boost with the European Commission's (EC) approval of Praluent (alirocumab) for a new indication. The approval enables ... Read More
Dupixent receives FDA approval for treatment of moderate-to-severe asthma
Sanofi and Regeneron Pharmaceuticals' Dupixent (dupilumab) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) approving it as an add-on maintenance ... Read More
FDA approves updated label for Regeneron’s EYLEA treating wet AMD
In a significant development for ophthalmic care, Regeneron Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License ... Read More
Teva and Regeneron report positive Phase 3 results for Fasinumab in osteoarthritis pain management
Teva Pharmaceutical Industries and Regeneron Pharmaceuticals have announced successful outcomes from their phase 3 study of fasinumab, a nerve growth factor (NGF) antibody, in patients ... Read More
Sanofi and Regeneron’s Dupixent receives FDA approval for atopic dermatitis treatment
Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug Administration (FDA) approving Dupixent (dupilumab) for the ... Read More
Sanofi and Regeneron’s Dupixent shows promising results in Phase 3 eczema trial
Sanofi and Regeneron Pharmaceuticals have achieved a significant milestone with their jointly developed eczema drug, Dupixent (dupilumab), meeting the primary endpoints in a year-long Phase ... Read More